Skip to content

Pharminent

Primary Menu
  • Home
    • Signal News
Light/Dark Button
Brief
  • Home
  • Policy / Pricing
  • Mid-cap biotechs join Trump’s latest round of drug pricing deals
  • Policy / Pricing

Mid-cap biotechs join Trump’s latest round of drug pricing deals

BioPharma Dive

Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren t expected to meaningfully impact drugmaker profits.

Read full story

pharminent September 1, 2026 (Last updated: September 2, 2026)

BioPharma Dive

Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren t expected to meaningfully impact drugmaker profits.

Read full story

Post navigation

Previous: Novartis says MS pill succeeds in two large studies
Next: Novartis Posts Phase 3 MS Win and Halts Eight Autoimmune CAR-T Trials

Related Stories

  • Policy / Pricing

MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones

pharminent August 27, 2026
  • Policy / Pricing

MFN affecting Swiss medicines access, says Interpharma

pharminent August 13, 2026
  • Policy / Pricing

Prior Authorization Metrics Provide New Insights into Insurer Practices, but Gaps Remain

pharminent August 13, 2026
  • Home
  • Contact
© 2026 All rights reserved. | ReviewNews by AF themes.